Neuronetics, Inc. (STIM) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Neuronetics, Inc. operates in two segments: Medical Device (sales of the NeuroStar Advanced Therapy System and treatment sessions) and Clinic Services (operations of Greenbrook TMS treatment centers). The company recently completed an acquisition of Greenbrook TMS Inc. effective December 9, 2024, which significantly impacts its revenue mix and operational structure.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $34.5 million | $32.0 million |
| Gross Profit | $16.2 million | $15.7 million |
| Gross Margin | 46.9% | 49.2% |
| Net Loss | $(10.8) million | $(12.7) million |
| Net Loss Per Share (Basic/Diluted) | $(0.16) | $(0.21) |
| Cash and Cash Equivalents | $13.2 million | $20.2 million (Q1 2025) |
| Long-Term Debt (Net) | $61.3 million | $65.8 million (Dec 31, 2025) |
| Operating Cash Flow | $(9.4) million | $(17.0) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 8% year-over-year, driven primarily by a 15% increase in Clinic Services revenue ($21.5M vs. $18.7M) following the Greenbrook acquisition. This was partially offset by a 5% decline in Treatment Session revenue.
- Margin Compression: Gross margin decreased from 49.2% to 46.9%, attributed to the revenue mix shift toward lower-margin clinic services.
- Expense Reduction: Operating expenses decreased 6% to $25.1 million. Sales and marketing expenses dropped 11% due to lower personnel costs and marketing spend. R&D expenses fell 16%.
- Debt Restructuring: The company made a $5.0 million principal payment on its Perceptive Credit Facility in March 2026, incurring a $0.5 million loss on debt extinguishment (including prepayment penalties).
- Other Income: Other income, net, increased significantly to $1.0 million (from $0.2 million) due to net proceeds from Employee Retention Credit (ERC) claims.
Outlook, Risks, and Contingencies
- Going Concern Warning: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. Management projects that trailing twelve-month revenue for the period ended March 31, 2027, will be below the minimum required revenue covenant in its credit facility.
- Liquidity Risk: If the lender calls the credit facility due to covenant breach, the company does not currently project having sufficient liquidity to repay the loan. The company is in active discussions with its lender to address this.
- Legal Proceedings: The company is cooperating with a Civil Investigative Demand from the U.S. Attorney's Office for the Middle District of Florida and a similar investigation by the Michigan Attorney General regarding federal healthcare program billing practices at its Greenbrook subsidiaries.
- Capital Resources: The company has an At-The-Market (ATM) equity offering program with approximately $41.7 million remaining available for issuance.
Investor Verification Checklist
- Covenant Compliance: Verify the specific revenue thresholds required for the March 31, 2027, covenant and the status of ongoing negotiations with Perceptive Credit Holding IV, LP.
- Cash Burn Rate: Monitor the trajectory of operating cash flow burn ($9.4M in Q1) against the current cash balance ($13.2M) to assess runway without additional financing.
- Legal Exposure: Track the outcome of the federal and state investigations into billing practices, which could result in penalties or exclusion from government programs.
- Revenue Mix: Analyze the sustainability of the clinic revenue growth versus the decline in treatment session sales to understand long-term margin implications.
- Debt Structure: Review the terms of the Perceptive Facility, specifically the prepayment penalties and the conditions under which the lender may call the loan.